Skip to main content
Terug
Watch Compare

Karyopharm Therapeutics Inc.

Datakwaliteit: 100%
KPTI
Nasdaq Manufacturing Chemicals
€ 8,00
▼ € 0,16 (-1,96%)
Marktkapitalisatie: 183,73 M
Prijs
€ 8,15
Marktkapitalisatie
183,73 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -8,66% annually over 5 years
Negative free cash flow of -75,37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 9,23%
Capital efficient — spends only 0,00% of revenue on capex

Groei

Revenue Growth (5Y)
-8,66%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)0,57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-972,43%
Net Margin-134,21%
Op. Margin-62,10%

Veiligheid

Debt / Equity
N/A
Current Ratio1,03
Interest Coverage-1,98

Waardering

PE (TTM)
-0,94
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % -134,2 -41,5
Rev Growth 5Y % -8,7 1,8
D/E — 0,3

Koersdoel Analisten

6 analisten
Buy
Huidig
€ 8,00
+37.5%
Koersdoel
€ 11,00
€ 5,00
€ 11,00
€ 16,00
Vooruitzicht
Forward K/W -1,83
Forward WPA -€ 4,37
Omzet Sch. 162,78 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 4,37
-€ 6,32 – -€ 2,41
 162,78 M 2
FY2026 -€ 4,78
-€ 6,22 – -€ 2,86
 137,49 M 3

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 2,00 -€ 2,23 -11,4%
Q32025 -€ 3,25 -€ 3,82 -17,5%
Q22025 -€ 3,91 -€ 4,07 -4,0%
Q12025 -€ 3,09 -€ 2,77 +10,3%

ETFs Holding This Stock

CNCR CNCR
1,22% weight
BRUSX BRUSX
0,41% weight
BRSIX BRSIX
0,04% weight
DLHAX DLHAX
0,04% weight
DLRHX DLRHX
0,04% weight
DLHIX DLHIX
0,04% weight
BDSKX BDSKX
0,01% weight
BDSCX BDSCX
0,01% weight
BDSAX BDSAX
0,01% weight
BDSIX BDSIX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,57% Revenue Growth (3Y) 0,01%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -8,66% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 146,07 M Net Income (TTM) -196,04 M
ROE N/A ROA -194,96%
Gross Margin N/A Operating Margin -62,10%
Net Margin -134,21% Free Cash Flow (TTM) -75,37 M
ROIC -972,43% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,03
Interest Coverage -1,98 Asset Turnover 1,45
Working Capital 2,59 M Tangible Book Value -269,26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,94 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1,26
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -41,02%
Market Cap 183,73 M Enterprise Value 146,06 M
Per Share
EPS (Diluted TTM) -17,93 Revenue / Share 6,48
FCF / Share -3,34 OCF / Share -3,34
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 38,45%
SBC-Adj. FCF -89,70 M Growth Momentum 9,23

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 146,07 M 145,24 M 146,03 M 157,07 M 209,82 M
Net Income -196,04 M -76,42 M -143,10 M -165,29 M -124,09 M
EPS (Diluted) -17,93 -0,93 -1,25 -2,02 —
Gross Profit — — — — —
Operating Income -90,71 M -119,44 M -129,54 M -142,20 M -98,27 M
EBITDA — — — — —
R&D Expenses 125,62 M 143,23 M 138,75 M 148,66 M 160,84 M
SG&A Expenses 105,21 M 115,44 M 131,88 M 145,40 M 143,85 M
D&A — — — — —
Interest Expense 45,85 M 37,42 M 23,82 M 25,00 M 26,05 M
Income Tax 43.000,0 57.000,0 323.000,0 369.000,0 268.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 108,42 M 164,42 M 240,44 M 358,17 M 305,31 M
Total Liabilities 401,34 M 350,44 M 376,64 M 374,83 M 384,98 M
Shareholders' Equity -292,93 M -186,02 M -136,21 M -16,66 M -79,67 M
Total Debt — — — — 169,29 M
Cash & Equivalents 60,54 M 62,48 M 52,23 M 135,19 M 190,46 M
Current Assets 103,15 M 156,49 M 233,92 M 350,16 M 275,61 M
Current Liabilities 92,06 M 92,26 M 69,48 M 65,91 M 73,72 M